Singapore markets closed

Cipla Limited (CIPLA.NS)

NSE - NSE Real-time price. Currency in INR
Add to watchlist
1,493.55+14.10 (+0.95%)
At close: 03:30PM IST
Full screen
Previous close1,479.45
Open1,475.25
Bid0.00 x 0
Ask0.00 x 0
Day's range1,472.60 - 1,497.60
52-week range942.30 - 1,519.00
Volume1,607,618
Avg. volume1,978,635
Market cap1.206T
Beta (5Y monthly)0.37
PE ratio (TTM)29.26
EPS (TTM)51.04
Earnings date24 Jul 2024 - 29 Jul 2024
Forward dividend & yield13.00 (0.88%)
Ex-dividend date01 Aug 2024
1y target est1,448.09
  • Reuters

    Indian drugmakers to see FY25 revenue boost in key US market, says India Ratings and Research

    Indian drugmakers, which have the U.S. market as a key segment, will sustain their revenue improvement in fiscal 2025 due to drug shortages in the United States, Mumbai-based India Ratings and Research said on Monday. India is a hub of bulk generic drug manufacturing and drugmakers including Dr Reddy's, Cipla, Sun Pharma derive a significant share of revenue from both the U.S. and Europe. The world's largest drug market is facing decade-high drug shortages, the research firm said in a note citing data from with Utah Drug Information Service.

  • Zacks

    Exelixis (EXEL) Settles Cabometyx Patent Litigation With Cipla

    Exelixis (EXEL) resolves two patent litigations and grants Cipla a license to market generic versions of Cabometyx in the United States beginning January 2031.

  • Reuters

    Promoter group to sell stake worth $316 million in India's Cipla, CNBC-TV18 reports

    Cipla's promoter group is looking to sell a 2.53% stake in India's third-largest drugmaker via a block deal worth 26.37 billion rupees (nearly $316 million), CNBC-TV18 reported on Tuesday, citing sources. The promoter group will sell its stake in Cipla at a per-share price range of 1,289.5 rupees to 1,357.35 rupees, the report said. Cipla did not immediately respond to a Reuters request for comment.